Business Description
Grace Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : CA00430K4028
Share Class Description:
GRCE: Ordinary SharesDescription
Grace Therapeutics Inc is a late-stage specialty pharma company with drug delivery technologies and drug candidates addressing rare and orphan diseases. The company's lead drug candidate, GTx-104, is a novel injectable formulation of nimodipine for the treatment of a rare disease, aneurysmal subarachnoid hemorrhage.
Financial Strength
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 632.08 | |||||
| Equity-to-Asset | 0.86 | |||||
| Interest Coverage | No Debt | |||||
| Piotroski F-Score | 2/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 27.3 | |||||
| 3-Year EPS without NRI Growth Rate | 34.7 | |||||
| 3-Year FCF Growth Rate | 34.2 | |||||
| 3-Year Book Growth Rate | -20 |
Momentum Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 36.2 | |||||
| 9-Day RSI | 44.11 | |||||
| 14-Day RSI | 48.28 | |||||
| 6-1 Month Momentum % | 2.5 | |||||
| 12-1 Month Momentum % | 43.23 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 6.01 | |||||
| Quick Ratio | 6.01 | |||||
| Cash Ratio | 5.67 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -29.4 | |||||
| Shareholder Yield % | 0.7 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -18.8 | |||||
| ROA % | -16 | |||||
| ROIC % | -26.49 | |||||
| ROC (Joel Greenblatt) % | -50312.5 | |||||
| ROCE % | -22.83 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 0.65 | |||||
| Price-to-Tangible-Book | 5.29 | |||||
| EV-to-EBIT | -0.88 | |||||
| EV-to-EBITDA | -0.88 | |||||
| EV-to-FCF | -1.19 | |||||
| Price-to-Net-Current-Asset-Value | 5.29 | |||||
| Price-to-Net-Cash | 6.1 | |||||
| Earnings Yield (Greenblatt) % | -113.64 | |||||
| FCF Yield % | -32.37 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:GRCE
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Grace Therapeutics Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -1.295 | ||
| Beta | 0.87 | ||
| Volatility % | 57.03 | ||
| 14-Day RSI | 48.28 | ||
| 14-Day ATR ($) | 0.376807 | ||
| 20-Day SMA ($) | 3.7965 | ||
| 12-1 Month Momentum % | 43.23 | ||
| 52-Week Range ($) | 1.98 - 4.965 | ||
| Shares Outstanding (Mil) | 10.14 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Grace Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Grace Therapeutics Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Grace Therapeutics Inc Frequently Asked Questions
What is Grace Therapeutics Inc(GRCE)'s stock price today?
The current price of GRCE is $3.60. The 52 week high of GRCE is $4.97 and 52 week low is $1.98.
When is next earnings date of Grace Therapeutics Inc(GRCE)?
The next earnings date of Grace Therapeutics Inc(GRCE) is 2025-02-12 Est..
Does Grace Therapeutics Inc(GRCE) pay dividends? If so, how much?
Grace Therapeutics Inc(GRCE) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers